According to an observational study conducted by a research team in Mount Sinai, New York, on August 26, an observational study by a team of researchers in Mount Sinai, New York, showed that in patients infected with new coronavirus, the risk of death was reduced by 50% for those using therapeutic doses of anticoagulants or blood thinners and those using prophylactic, i.e., lower doses of hemodilution drugs, and the need for endotracheal intubation was reduced by 30%. The study was published in the weekly. “Obviously, anticoagulation is associated with improved efficacy, and the bleeding rate appears to be low,” said Anu Lala, associate professor of medicine at Mount Sinai ICAM medical school and head of heart failure research. Novel coronavirus pneumonia is a new clinician who has been treated as a first-line treatment for new crown pneumonia. I know what is the best way of treatment for these patients. These results will contribute to the design of clinical trials, and clinical trials will eventually provide accurate information. < / P > < p > the researchers said the study followed the discovery of blood clots in many new coronavirus infected patients. The researchers said they investigated the survival and mortality of patients treated with therapeutic and preventive doses of blood thinners, including oral antithrombotic drugs, subcutaneous heparin and intravenous heparin, compared with those who did not use anticoagulants. < / P > < p > the researchers analyzed 4389 medical records of patients diagnosed with new coronavirus in the Mount Sinai Medical System in New York City between March 1 and April 30, 2020. < / P > < p > in the treatment and prevention groups, six different hemodilution treatments were evaluated. Compared with other drugs, subcutaneous low molecular weight heparin and therapeutic oral drug apixaban have the best effect. The researchers considered various factors and used risk scores to estimate the risk of death. < / P > < p > compared with those who did not use blood thinners, the risk of death during hospitalization was reduced by nearly 50% in patients using full and preventive doses of anticoagulants, which were closely related to blood thinners, the authors of the study found. In novel coronavirus pneumonia patients who received full dose and low dose therapeutic blood thinners, the treatment of endotracheal intubation was also less, with a decrease of 31% and 28% respectively. < / P > < p > the researchers also studied the bleeding rate because of the risks associated with the use of anticoagulants. The researchers found that bleeding rates were “surprisingly low” in all patients, with only 3% of cases occurring.
researchers found novel coronavirus pneumonia patients after autopsy found that in 26 patients, 11 people have clinical environment in the blood clot not suspected. They concluded that novel coronavirus pneumonia patients may be prevented from using blood thinners to prevent clots formation. The observational study lays the foundation for a larger global clinical trial being coordinated by the research team, said Valentin foster, senior author of the study. The clinical trial will “focus on three antithrombotic methods: therapeutic and prophylactic subcutaneous injection of low molecular weight heparin and therapeutic oral administration of apixaban,” said foster, chief physician at Mount Sinai Hospital. 20